(naphthalen-1-ylmethylene)-3,4,5-trimethoxyphenylamine | 387850-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (naphthalen-1-ylmethylene)-3,4,5-trimethoxyphenylamine
• 英文别名: 3,4,5-trimethoxy-N-(naphthalen-1-ylmethylene)aniline
• CAS: 387850-50-2
• 化学式: C₂₀H₁₉NO₃
• 分子量: 321.376
• InChiKey: OZCUSLHOKVAVJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.62
• 重原子数：
  24.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  40.05
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (naphthalen-1-ylmethylene)-3,4,5-trimethoxyphenylamine 在 三正丙胺 、 2-氯-1-甲基吡啶碘化物 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 36.0h， 生成 dimethyl-6-(1-(3,4,5-trimethoxyphenyl)-2-(naphthalen-1-yl)-4-oxoazetidin-3-yl)cyclohexa-1,3-diene-1,2-dicarboxylate
  参考文献：
  名称：

  3-(Prop-1-en-2-yl)azetidin-2-Ones 及相关化合物在 MCF-7 和 MDA-MB-231 乳腺癌细胞中的抗增殖和微管蛋白失稳作用

  摘要：

  一系列新型3-(prop-1-en-2-yl)azetidin-2-one、3-allylazetidin-2-one和3-(buta-1,3-dien-1-yl)azetidin-2-设计并合成了考布他汀 A-4 (CA-4) 的一种类似物作为秋水仙碱结合位点抑制剂 (CBSI)，其中 CA-4 的乙烯桥被 β-内酰胺 (2-氮杂环丁酮) 支架取代。对这些化合物以及相关前药的抗增殖活性、细胞周期效应和抑制微管蛋白组装的能力进行了评估。这些化合物在 MCF-7 乳腺癌细胞中表现出显着的体外抗增殖活性，特别是化合物 9h、9q、9r、10p、10r 和 11h，IC50 值在 10-33 nM 范围内。这些化合物在三阴性乳腺癌 (TBNC) 细胞系 MDA-MB-231 中也有效，IC50 值在 23-33 nM 范围内，并且与 CA-4 的活性相当。这些化合物在体外抑制微管蛋白的聚合，显着

  DOI：

  10.3390/ph16071000
• 作为产物：
  描述：

  1-萘甲醛 、 3,4,5-三甲氧基苯胺 以 乙醇 为溶剂， 反应 3.0h， 以77%的产率得到(naphthalen-1-ylmethylene)-3,4,5-trimethoxyphenylamine
  参考文献：
  名称：

  靶向抗微管蛋白的氮杂环丁烷-2-酮的合成，评价和结构研究

  摘要：

  合成一系列在氮杂环丁酮环骨架的1、3和4位取代的氮杂环丁烷-2-酮，并评估其抗增殖，细胞毒性和微管蛋白结合活性。在这些化合物中，血管靶向剂康维他汀A-4的顺式双键被氮杂环丁酮环取代，以增强康维他汀A-4表现出的抗增殖作用并防止与康维他汀失活有关的顺/反异构化A-4。氮杂环丁酮系列可通过Staudinger和Reformatsky反应合成得到。在各种杂环衍生物中，3-（2-噻吩基）类似物28和3-（3-噻吩基）类似物29在人MCF-7乳腺癌细胞中显示出最高的功效，其IC 50值分别为7 nM和10 nM，与康布雷他汀A-4相当。该系列化合物在MDA-MB-231乳腺癌细胞和NCI60细胞系中也显示出强大的活性。在正常鼠乳腺上皮细胞中未观察到明显的毒性。在3-位上存在较大，较大的基团，例如3-萘基衍生物21和3-苯并噻吩基衍生物26，导致在微摩尔范围内相对较低的抗增殖活性。微管蛋白结合研究28（IC

  DOI：

  10.1016/j.bmc.2011.02.022

文献信息

• 3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells
  作者：Wang、Malebari、Greene、O’Boyle、Fayne、Nathwani、Twamley、McCabe、Keely、Zisterer、Meegan

  DOI：10.3390/ph12020056

  日期：——

  Microtubule-targeted drugs are essential chemotherapeutic agents for various types of cancer. A series of 3-vinyl-β-lactams (2-azetidinones) were designed, synthesized and evaluated as potential tubulin polymerization inhibitors, and for their antiproliferative effects in breast cancer cells. These compounds showed potent activity in MCF-7 breast cancer cells with an IC50 value of 8 nM for compound 7s 4-[3-Hydroxy-4-methoxyphenyl]-1-(3,4,5-trimethoxyphenyl)-3-vinylazetidin-2-one) which was comparable to the activity of Combretastatin A-4. Compound 7s had minimal cytotoxicity against both non-tumorigenic HEK-293T cells and murine mammary epithelial cells. The compounds inhibited the polymerisation of tubulin in vitro with an 8.7-fold reduction in tubulin polymerization at 10 M for compound 7s and were shown to interact at the colchicine-binding site on tubulin, resulting in significant G2/M phase cell cycle arrest. Immunofluorescence staining of MCF-7 cells confirmed that β-lactam 7s is targeting tubulin and resulted in mitotic catastrophe. A docking simulation indicated potential binding conformations for the 3-vinyl-β-lactam 7s in the colchicine domain of tubulin. These compounds are promising candidates for development as antiproiferative microtubule-disrupting agents.

  微管靶向药物是各种癌症的重要化疗药物。一系列3-乙烯基-β-内酰胺（2-氮杂环丙酮）被设计、合成并评估为潜在的微管聚合抑制剂，以及它们在乳腺癌细胞中的抗增殖效应。这些化合物在MCF-7乳腺癌细胞中表现出强大的活性，其中化合物7s（4-[3-羟基-4-甲氧基苯基]-1-(3,4,5-三甲氧基苯基)-3-乙烯基氮杂环丙酮）的IC50值为8 nM，与康布雷他定A-4的活性相当。化合物7s对非肿瘤性HEK-293T细胞和小鼠乳腺上皮细胞均具有最小的细胞毒性。这些化合物在体外抑制了微管的聚合，在10 μM的浓度下，化合物7s使微管聚合减少了8.7倍，并且显示出它们与微管上的秋水仙碱结合位点相互作用，导致显著的G2/M期细胞周期阻滞。MCF-7细胞的免疫荧光染色证实了β-内酰胺7s靶向微管，并导致有丝分裂灾难。对于3-乙烯基-β-内酰胺7s在微管秋水仙碱结合区域的潜在结合构象进行的对接模拟表明了潜在的结合构象。这些化合物是作为抗增殖微管破坏剂的发展有前途的候选药物。
• Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4
  作者：Azizah M. Malebari、Shu Wang、Thomas F. Greene、Niamh M. O’Boyle、Darren Fayne、Mohemmed Faraz Khan、Seema M. Nathwani、Brendan Twamley、Thomas McCabe、Daniela M. Zisterer、Mary J. Meegan

  DOI：10.3390/ph14111119

  日期：——

  development of multidrug resistance has limited their clinical activity. We report the synthesis and biological properties of a series of novel 3-chloro-β-lactams and 3,3-dichloro-β-lactams (2-azetidinones) that are structurally related to the tubulin polymerisation inhibitor and vascular targeting agent, Combretastatin A-4. These compounds were evaluated as potential tubulin polymerisation inhibitors and for

  以微管蛋白为靶点的抗有丝分裂药物是最广泛使用的化疗药物之一。然而，多重耐药性的发展限制了它们的临床活性。我们报道了一系列新型 3-氯-β-内酰胺和 3,3-二氯-β-内酰胺（2-氮杂环丁酮）的合成和生物学特性，它们在结构上与微管蛋白聚合抑制剂和血管靶向剂 Combretastatin A 相关-4。这些化合物被评估为潜在的微管蛋白聚合抑制剂及其对乳腺癌细胞的抗增殖作用。许多化合物在 MCF-7 乳腺癌细胞中显示出有效的活性，例如化合物10n (3-氯-4-(3-羟基-4-甲氧基-苯基)-1-(3,4,5-三甲氧基苯基)氮杂环丁烷-2-酮)和化合物11n (3,3-二氯-4-(3-羟基-4-甲氧基苯基)-1-(3,4,5-三甲氧基苯基)-氮杂环丁烷-2-酮)，IC 50值分别为 17 和 31 nM，并且显示出与 Combretastatin A-4 相当的细胞效应。化合物10n对非致瘤性 HEK-293T
• Visible-Light-Driven Enantioselective Radical Addition to Imines Enabled by the Excitation of a Chiral Phosphoric Acid–Imine Complex
  作者：Tatsuhiro Uchikura、Nanami Kamiyama、Toshiki Mouri、Takahiko Akiyama

  DOI：10.1021/acscatal.2c00993

  日期：2022.5.6

  A visible-light-driven enantioselective radical addition to imines enabled by the direct excitation of a chiral phosphoric acid–imine complex was developed. By using benzothiazolines as the radical precursors, chiral amine products were obtained with high enantioselectivities (up to 98% ee). Mechanistic studies elucidated that the chiral phosphoric acid–imine complex has photoredox activities for oxidizing

  通过手性磷酸-亚胺复合物的直接激发，开发了一种可见光驱动的对亚胺的对映选择性自由基加成。通过使用苯并噻唑啉作为自由基前体，获得了具有高对映选择性（高达 98% ee）的手性胺产物。机理研究表明，手性磷酸-亚胺复合物具有氧化苯并噻唑啉的光氧化还原活性。
• Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents
  作者：Thomas F. Greene、Shu Wang、Lisa M. Greene、Seema M. Nathwani、Jade K. Pollock、Azizah M. Malebari、Thomas McCabe、Brendan Twamley、Niamh M. O’Boyle、Daniela M. Zisterer、Mary J. Meegan

  DOI：10.1021/acs.jmedchem.5b01086

  日期：2016.1.14

  Structure-activity relationships for a series of 3-phenoxy-1,4-diarylazetidin-2-ones were investigated, leading to the discovery of a number of potent antiproliferative compounds, including trans-4-(3-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (78b) and trans-4-(3-amino-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (90b). X-ray crystallography studies indicate the potential importance of the torsional angle between the 1-phenyl A ring and 4-phenyl B ring for potent antiproliferative activity and that a trans configuration between the 3-phenoxy and 4-phenyl rings is generally optimal. These compounds displayed IC50 values of 38 and 19 nM, respectively, in MCF-7 breast cancer cells, inhibited the polymerization of isolated tubulin in vitro, disrupted the microtubular structure in MCF-7 cells as visualized by confocal microscopy, and caused G(2)/M arrest and apoptosis. Compound 90b possessed a mean GI50 value of 22 nM in the NCI60 cell line screen, displayed minimal cytotoxicity, and was shown to interact at the colchicine-binding site on beta-tubulin. Phosphate and amino acid prodrugs of both 78b and 90b were synthesized, of which the alanine amide 102b retained potency and is a promising candidate for further clinical development.